Using Misoprostol to Reduce Blood Loss After Cesarean Section
The Effect of Pre-operative Versus Post-operative Misoprostol in Reducing Blood Loss During and After Elective Cesarean Section.
This study is testing whether giving Misoprostol before or after a cesarean section can help reduce blood loss for women having the surgery.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 120 (estimated) |
| Ages | 20 Years to 40 Years |
| Sex | Female |
| Sponsor | Cairo University Academic / other |
| Locations | 1 site (Cairo) |
| Trial ID | NCT05928871 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effectiveness of administering Misoprostol before versus after a cesarean section to reduce blood loss during and after the procedure. The study involves detailed patient history taking and clinical examinations to ensure eligibility, focusing on women scheduled for elective cesarean sections. Participants will receive a 200mcg tablet of Misoprostol, which is known for its utero-tonic properties, to assess its impact on postpartum hemorrhage rates. The trial aims to provide insights into alternative strategies for managing blood loss in cesarean deliveries.
Who should consider this trial
Good fit: Ideal candidates are women aged 18-40 with singleton, full-term pregnancies scheduled for elective cesarean sections.
Not a fit: Patients with contraindications to prostaglandins, such as a history of severe asthma or allergy to Misoprostol, will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly reduce the incidence of postpartum hemorrhage, improving maternal health outcomes.
How similar studies have performed: Other studies have shown promising results with the use of Misoprostol in similar contexts, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Women booked for elective cesarean section not in active labor * Scheduled for primary elective caesarian section. * No contraindications to prostaglandins. * Have no history of coagulopathy. * Aged between 18-40 years. * Full term pregnancies (GA 37 to 42 weeks). * Singleton pregnancies. * BMI 20-30 kg/ m2 Exclusion Criteria: * Placenta previa. * Maternal hypertension and Pre-eclampsia. . * Diabetes mellitus. * Previous CS and those with active labor. * Multiple Fibroid uterus . * Multiple pregnancies. * Overdistended uterus eg. polyhydramnios * Previous myomectomy, previous history of PPH . * Contraindication to spinal anesthesia. * Blood coagulopathy and bleeding disorder. * Marked maternal anemia (Preoperative hemoglobin \<9 gm/dl). * Contraindications to prostaglandin therapy (e.g. history of severe bronchial asthma or allergy to misoprostol. * Extreme of BMI (\<20 or \>30Kg/m2).
Where this trial is running
Cairo
- faculty of medicine, Kasr el ainy hospital, Cairo university — Cairo, Egypt (Recruiting)
Study contacts
- Principal investigator: Mohammed A Taymour, MD — Cairo University
- Study coordinator: waleed M El-khayat, MD
- Email: waleed_elkhyat@yahoo.com
- Phone: 01005135542
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.